Author Archive

Anaeropharma Science Signs Collaborative Research Agreement with Chugai on Creation of Novel Oncology Drugs Using Bifidobacterium

Anaeropharma Science Inc. headquartered in Tokyo (hereinafter “Anaeropharma”) announced on October 22 that Anaeropharma Science and Chugai Pharmaceutical Co., Ltd. headquartered in Tokyo (hereinafter “Chugai”) have concluded a collaborative research agreement concerning the creation of novel oncology drugs utilizing characteristic features of Bifidobacterium longum through Anaeropharma’s proprietary platform technology, “in situ Delivery and Production System” (hereinafter “i-DPS”). An overview of the contract follows.

 

  1. A collaborative research agreement concerning the creation of novel oncology drugs utilizing i-DPS technology

Under the agreement, Anaeropharma and Chugai conduct joint research regarding specific oncology substances by use of Anaeropharma’s i-DPS technology and Chugai’s technology. The scope of the agreement is limited to the specific substances predetermined by both companies, and the i-DPS technology will be applied only to those substances.

 

  1. About i-DPS and its development programs

Bifidobacterium is obligatory anaerobe which exists as enteroflora in the human body, and known as nonpathogenic bacteria. Solid cancers have immature vascular constructs and their interstitial tumors are in the state of hypoxia. The company aims to leverage the recombinant Bifidobacterium technology to create a new class of anti-cancer drugs. The technology offers broad potential of being more effective to solid tumors and generates oncology drugs with less risks of adverse events than conventional anti-cancer drugs.

 

The leading product developed using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S.

 

  1. About Anaeropharma Science, Inc.

A privately held biopharmaceutical company based in Chiyoda-ku, Tokyo, Japan, Anaeropharma Science was established to pioneer the development of novel therapeutics to target a hypoxic environment in solid cancers based on its proprietary platform technology, i-DPS, using recombinant Bifidobacterium. The company’s laboratory is located in the campus of Shinshu University in Matsumoto, Nagano Prefecture. Its CEO is Tetsuya Mishima.

PDF download here


Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium

Anaeropharma Science Inc. headquartered in Tokyo ( hereafter “Anaeropharma”) announced on September 25 that Anaeropharma and Astellas Pharma Inc. headquartered in Tokyo ( hereafter “Astellas”) have concluded a collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes characteristic features of Bifidobacterium longum through Anaeropharma’s proprietary platform technology, in situ Delivery and Production System ( “i-DPS”). An overview of the contract follows.

1. A collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes i-DPS technology

Under the terms of the agreement, the two companies shall conduct joint research regarding specific substances in order to create drug candidates for cancer therapy that utilizes Bifidobacterium as a drug delivery carrier. Astellas shall acquire the right of first negotiation regarding the exclusive licensing necessary for commercialization based on the results of this joint research. The agreement shall not constrain any research and development activities of i-DPS conducted by Anaeropharma applying to any molecules other than the above-mentioned specific substances.

2. About i-DPS and its Development Programs

Bifidobacterium is obligatory anaerobe which exists as enteroflora in the human body, and known as nonpathogenic bacteria. Solid cancers have immature vascular constructs and their interstitial tumors are in the state of hypoxia. The company aims to leverage the recombinant Bifidobacterium technology named i-DPS to create a new class of anti-cancer drugs. The technology offers broad potential to be more effective to solid tumors and generates anti-tumor drugs with less risks of adverse events than conventional anti-cancer drugs.

The leading development product using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S.

3. About Anaeropharma Science, Inc.

A privately held biopharmaceutical company based in Chiyoda-ku, Tokyo, Japan. Anaeropharma Science was established to pioneer the development of novel therapeutics to target a hypoxic environment in solid cancers based on its proprietary platform technology, i-DPS, using recombinant Bifidobacterium. The company’s laboratory is located in the campus of Shinshu University in Matsumoto, Nagano Prefecture. Its CEO is Tetsuya Mishima.

PDF download here


Head office relocation announcement

We are pleased to announce that our head office will relocate to the following address as of April 11, 2018.
Tokyo Park Tower 201, 1-103 Kanda Jinbocho,
Chiyoda-ku, Tokyo 101-0051, JAPAN


Anaeropharma Science announces appointment of new Board Director

Dr. Yoshimatsu has been named the new Board Director of Anaeropharma Science. He started this new role from March 2018. Prior to this, he spent 40 years in leading research activities mainly in the oncology area at Eisai, one of the leading Japanese pharmaceutical companies.


Anaeropharma Science will be presenting its latest research outcomes regarding agonistic antibody producing recombinant Bifidobacterium at the 2018 Annual Meeting of the AACR

Anaeropharma Science will be presenting its latest research outcomes towards agonistic anti-4-1BB scFv antibody producing recombinant Bifidobacterium at the 2018 Annual Meeting of the AACR (American Association for Cancer Research), which takes place from April 14 to 18 in Chicago, the poster is titled Cancer immunotherapy with agonistic anti-4-1BB producing and secreting Bifidobacterium in syngeneic mouse model”, which will be presented on Apr. 16, from 1:00 PM to 5:00 PM, in the session of immune checkpoint 2.


Anaeropharma has presented new research outcomes at AACR Conference on Tumor Immunology and Immunotherapy

At AACR Special Conference on Tumor Immunology and Immunotherapy took place October 1-4, 2017 in Boston, MA, Anaeropharma has presented its new research outcomes regarding cancer immunotherapy titled “Anti-PD-1 antibody scFv producing recombinant Bifidobacterium exerts antitumor effect in a larger fraction of the treated mice comparing to full length anti-PD-1 antibody”.

PDF download here

 


Anaeropharma Science Announces Closing of Financing

TOKYO, July 5, 2017

Anaeropharma Science, Inc., a company dedicated to the development of novel therapeutics to target hypoxic solid tumors, announced on July 5 it has secured US$13.2 million in new capital. The participants in the financing round include three new investors, Novartis, Shinsei Corporate Investment Limited and Seventure Partners’ Health for Life Capital fund, and two existing investors, Innovation Network Corporation of Japan and Mitsubishi UFJ Capital’s managed fund. Anaeropharma will use the financing to accelerate the development of multiple programs based on its proprietary platform technology.

About Anaeropharma Science, Inc.

Anaeropharma is a biopharmaceutical company engaged in research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant Bifidobacterium. This approach offers broad potential to be more effective to solid tumors and less toxic to healthy tissues than conventional anti-cancer drugs. APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is its leading development product which is under a clinical trial in the U.S., and additional programs in the immune oncology area such as immune checkpoint blockers and other immune-related molecules expressing recombinant Bifidobacteria are under active development.

PDF download here


Anaeropharma Science will be presenting its latest research outcomes at the 2017 Annual Meeting of the AACR

Anaeropharma Science will be presenting its latest research outcomes towards combination approaches of its i-DPS therapy with immune checkpoint inhibitor at the 2017 Annual Meeting of the AACR (American Association for Cancer Research), which takes place from April 1st to the 5th in Washington D.C.

The first poster is titled “Synergistic anti-tumor efficacy of combination therapy with APS001F, a cytosine deaminase (CD) expressing Bifidobacterium, 5-fluorocytosine (5-FC) and anti-mPD-1 antibody in syngeneic mice model”, which will be presented on Apr. 4th, from 1:00 PM to 5:00 PM, in the session of Clinical Immunotherapy, Viruses, and Bacteria.

PDF download here

The second one is titled “Enhanced anti-tumor effects by a combination approach of interferon-γ producing recombinant Bifidobacterium and anti-mPD-1 antibody in CT26 syngeneic mouse model”, which will be presented on Apr. 3rd, from 1:00 PM to 5:00 PM, in the session of Checkpoints 2: Small-Molecule Inhibitors.

PDF download here


Anaeropharma will present new research outcomes at AACR Conference on Tumor Immunology and Immunotherapy

At upcoming AACR Special Conference on Tumor Immunology and Immunotherapy taking place October 20-23, 2016 in Boston, MA, Anaeropharma will present its new research outcomes regarding cancer immunotherapy titled “Anti-CTLA-4 antibody scFv producing recombinant Bifidobacterium secretes CTLA-4 blocker specifically inside hypoxic tumor and suppresses tumor growth in syngeneic mice model”.

PDF download here


Anaeropharma has presented at 20th JFCR-ISCC (Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy)

At 20th JFCR-ISCC held in December 2015, Anaeropharma has presented its progress on immune checkpoint blocker producing B. longum which titled in “i-DPS (in situ Delivery and Production System): A “smart” Drug Delivery System to Produce Immune Checkpoint Blockers inside Hypoxic Tumor”.